ALT - NASDAQ
Altimmune, Inc.
$2.87
-1.0%Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
At a Glance
Live SnapshotAltimmune, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Altimmune, Inc. Income Statement
ALT • NASDAQ
| Altimmune, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
41K | 20K | 426K | -68K | 4.4M | 8.2M | 5.8M | 10.3M | 41.5K | 5.2M | 10.6M | 10.2M | 17.9M | 25.2M | 24.3M | 21M | 27.5M | 32.9M | 14.6M | 1.8M | |
GROSS PROFIT | ||||||||||||||||||||
(112K) | (0.0) | (0.0) | (0.0) | (0.0) | (33.5M) | (17.1M) | (18.5M) | (18.4M) | (7.2M) | (5.1M) | (4.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-71K | 20K | 426K | -68K | 4.4M | -25.3M | -11.3M | -8.1M | -18.4M | -2M | 5.6M | 5.9M | 17.9M | 25.2M | 24.3M | 21M | 27.5M | 32.9M | 14.6M | 1.8M | |
OPERATING INCOME | ||||||||||||||||||||
(94.5M) | (103.2M) | (96.4M) | (87.7M) | (101.3M) | (29.5M) | (26.3M) | (28.2M) | (16.2M) | (16.5M) | (11.5M) | (20.4M) | (28.8M) | (31.4M) | (36M) | (44.5M) | (53.5M) | (52M) | (31.1M) | (644.4K) | |
(28.1M) | (21M) | (18.1M) | (17.1M) | (15.4M) | (13.2M) | (8.5M) | (9.8M) | (8.5M) | (11.5M) | (6.2M) | (10.9M) | (13.3M) | (11.6M) | (14.3M) | (18M) | (22.4M) | (19.4M) | (13.9M) | (491.1K) | |
(66.4M) | (82.2M) | (65.8M) | (70.5M) | (74.5M) | (49.8M) | (17.8M) | (18.5M) | (18.4M) | (4.8M) | (5.1M) | (9.3M) | (15.3M) | (19.5M) | (21.2M) | (20.9M) | (30.2M) | (31.8M) | (16.6M) | (0.0) | |
-94.5M | -103.2M | -95.9M | -87.7M | -96.9M | -54.8M | -21.5M | -42.8M | -52M | -11.3M | -3.4M | -10.2M | -10.8M | -6.3M | -11.7M | -23.6M | -26M | -35.2M | -16.5M | 1.2M | |
PRE-TAX INCOME | ||||||||||||||||||||
(1.6M) | (9K) | (35K) | (8K) | (5K) | (9.4K) | (2.2K) | (297.1K) | (162.1K) | (38.5K) | (54.6K) | (210.4K) | (369.3K) | (342.6K) | (54.6K) | (5.9M) | (2.8M) | (2.6M) | (2.1M) | (0.0) | |
5.9M | 8.1M | 7.3M | 2.9M | 198K | 313.1K | 841.2K | -70.5K | -114.6K | -37.5K | -54.6K | -210.4K | -366.7K | -324.8K | -37.9K | -5.9M | -2.6M | -1.3M | -1M | 1.8M | |
(0.0) | (0.0) | (12.4M) | (0.0) | (11.4M) | -33.5M | (0.0) | (277.9K) | (5.7K) | (7.8K) | (8.1K) | -762.0 | -6.1K | (47.9K) | (461.1K) | (5.7M) | (872.3K) | (813.9K) | (705.4K) | (153.3K) | |
5.7M | 8.1M | 7.5M | 2.8M | -176K | 11.2M | 886.3K | -2.5M | -18.5K | 4.9K | 3.2M | 297.7K | -4.6M | -758.2K | 7.9M | -11.3M | -6.3M | -1.2M | 2.9M | 15.7M | |
-88.8M | -95.1M | -88.4M | -84.9M | -97.1M | -43.6M | -20.6M | -45.3M | -52.1M | 205M | -3.4M | -9.9M | -11.7M | -4.7M | -3,797.6B | -34,849.3B | -32.3B | -36.4B | -13.6M | 1.2M | |
NET INCOME | ||||||||||||||||||||
-681K | (0.0) | (0.0) | -197K | (0.0) | (5.4M) | -58.5K | -6.1M | -5.6M | (11.2M) | (61.7K) | (61.7K) | (61.7K) | (195.5K) | -7.9M | (15.9M) | (6.3M) | (17.3M) | (0.0) | (187K) | |
-88.1M | -95.1M | -88.4M | -84.7M | -97.1M | -49M | -20.5M | -39.2M | -46.4M | 193.9M | -3.4M | -10M | -11.7M | -4.9M | -3.8M | -34.8M | -32.3M | -36.4M | -13.6M | 1M |
SEC Filings
ALT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 16, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 17, 2026 | April 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 06, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 28, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 19, 2025 | 2025 |
Related Guides
Continue your ALT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.